Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 15, Issue 11, 2009, Pages 1721-1736

  Reiff, C ^a   Delday, M ^a   Rucklidge, G ^a   Reid, M ^a   Duncan, G ^a   Wohlgemuth, S ^c   Hormannsperger G ^b   Loh, G ^c   Blaut, M ^c   Collie Duguid, E ^d   Haller, D ^b   Kelly, D ^a  

^a ROWETT RESEARCH INSTITUTE   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Affymetrix; IBD; IL10; Knockout; Probiotic

Indexed keywords

CELL NUCLEUS RECEPTOR; CXCL9 CHEMOKINE; GALECTIN 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENE PRODUCT; INTEGRIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; PROTEIN IRGM; PROTEIN NR1D2; RANTES; RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VSL3; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DOWN REGULATION; DRUG MECHANISM; ENTERITIS; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICROARRAY ANALYSIS; MICROBIAL DIVERSITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; STREPTOCOCCUS THERMOPHILUS; T LYMPHOCYTE; UPREGULATION; WILD TYPE;

ANIMALS; CECUM; CHEMOKINE CCL5; COLON; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; LIPID METABOLISM; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHAGOCYTOSIS; PROBIOTICS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOCOCCUS THERMOPHILUS; XENOBIOTICS;

EID: 71949095393     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20999     Document Type: Article

References (65)

1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
2. Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis. 2007;13:1153-1164. (Pubitemid 47402601)
3. Steed H, Macfarlane GT, Macfarlane S. Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res. 2008;52:898-905.
4. Chapman TM, Plosker GL, Figgit DP. VSL#3 probiotic mixture. A review of its use in chronic inflammatory bowel disease. Drugs. 2006;66:1371-1387.
5. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591. (Pubitemid 32822573)
6. Caballero-Franco C, Keller K, De Simone C, et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2007;292:315-322.
7. Kühbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833-841. (Pubitemid 43764555)
8. Gaudier E, Michel C, Segain JP, et al. The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucosal barrier in mice. J Nutr. 2005;135:2753-2761.
9. Schlee M, Harder J, Koten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol. 2008;151:528-535. (Pubitemid 351160737)
10. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14:662-668.
11. Patent application number: 10/589,544; Publication number: US 2007/0128303 A1; Filing date: Feb. 4, 2005.
12. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J Clin Invest. 1996;98:1010-1020. (Pubitemid 26293320)
13. Gentleman RC, Carey V, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
14. Wu Z, Irizarry RA, Gentleman R, et al. A model based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc. 2004;99:909-917.
15. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, et al, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005:397-420.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methol). 1995;57:289-300.
17. Alexa A, Rahnenfuhrer J, Lengauer T, et al. Improving scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics. 2006;33:1600-1607.
18. Cavalieri D, Castagnini C, Toti S, et al. Eu.Gene Analyzer a tool for integrating gene expression data with pathway databases. Bioinformatics. 2007;23:2631-2632. (Pubitemid 350048370)
19. Walter J, Hertel C, Tannock GW, et al. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturant gradient gel electrophoresis. Appl Env Microbiol. 2001;67:2578-2585. (Pubitemid 33639729)
20. Satokari RM, Vaughan EE, Akkermans ADL, et al. Bifidobacterial diversity in human feces detected by genus-specific PCR and denaturant gradient gel electrophoresis. Appl Env Microbiol. 2001;67:504-513.
21. Tilsala-Timisjärvi A, Alatossava T. Development of oligonucleotide primers from the 16S-23S rRNA intergenic sequences for identifying different dairy and probiotic lactic acid bacteria by PCR. Int J Food Microbiol. 1997;35:49-56.
22. Brigidi P, Vitali B, Swennen E, et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol. 2001;152:735-741. (Pubitemid 32905506)
23. Dave RI, Shah NP. Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, and Bifidobacteria. J Dairy Sci. 1996;76:1529-1536.
24. Ulanova M, Gravelle S, Barnes R. The role of epithelial integrin receptors in recognition of pulmonary pathogens. J Innate Immun. 2009;1:4-17.
25. Gantner BN, Simmons RM, Canavera SJ. Collaborative induction of inflammatory responses by Dectin-1 and Toll-like Receptor 2. J Exp Med. 2003;197:1107-1117. (Pubitemid 36570066)
26. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol. 2008;8:411-420. (Pubitemid 351733416)
27. Levin A, Shibolet O. Toll-like receptors in inflammatory bowel disease - stepping into uncharted territory. World J Gastroenterol. 2008;14:5149-5153.
28. Kano S, Sato K, Morishita Y, et al. The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat Immunol. 2008;9:34-41. (Pubitemid 350286201)
29. Unutmaz D, Vilcek J. IRF1: a deus ex machina in TH1 differentiation. Nat Immunol. 2008;9:9-10. (Pubitemid 350286195)
30. Djuretic IM, Levanon D, Negreanu V, et al. Transcription factors T-bet and Runx3 cooperate to activate IFNγ and silence IL4 in T helper type 1 cells. Nat Immunol. 2007;:145-153.
31. Mikhak Z, Fleming CM, Medoff BD, et al. Stat1 in peripheral tissue differentially regulates homing of antigen specific TH1 and TH2 cells. J Immunol. 2006;176:4959-4967.
32. Zhao J, Kong HJ, Li H, Huang B, et al. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J Biol Chem. 2006;281:10073-10080.
33. Thompson EC, Cobb BS, Sabbattini P, et al. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity. 2007;26:335-344.
34. Kamath MB, Houston IB, Janovski AJ, et al. Dose-dependent repression of T-cell and natural killer cell genes by PU.1 enforces myeloid and B-cell identity. Leukemia. 2008;22:1214-1225.
35. Nunn AV, Bell J, Barter P. The integration of lipid-sensing and antiinflammatory effects: how the PPARs play a role in metabolic balance. Nucl Recept. 2007;5:1.
36. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARc and RelANat Immunol. 2004;5:104-112.
37. 2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-c in the intestinal mucosa. Gastroenterology. 2008;135:1216-1227.
38. Ramakrishnan SN, Muscat GE. The orphan Rev-erb nuclear receptors: a link between metabolism, circadian rhythm and inflammation?Nucl Recept Signal. 2006:e009.
39. Paclik D, Lohse K, Wiedenmann B. Galectin-2 and -4, but not Galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Inflamm Bowel Dis. 2008;14:1366-1372.
40. Paclik D, Berndt U, Guzy C, et al. Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J Mol Med. 2008;86:1395-1406.
41. Franke A, Balschun T, Karlsen TH. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008;40:713-715.
42. Franke A, Balschun T, Karlsen TH, et al. Sequence varients in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Gen. 2008;40:1319-1323.
43. Zhang H, Massey D, Tremelling M, et al. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull. 2008;87:17-30.
44. Rodriguez-Bores L, Fonseca GC, Villeda MA, et al. Novel genetic markers in inflammatory bowel disease. World J Gastroenetrol. 2007;13:5560-5570. (Pubitemid 350031475)
45. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Gen. 2008;39:830-832.
46. McCarrol SA, Huett A, Kuballa P, et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Gen. 2008;40:1107-1112.
47. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 2008;43:842-848. (Pubitemid 351918523)
48. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
49. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114. (Pubitemid 38083018)
50. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464. (Pubitemid 30636526)
51. Soo I, Madsen KL, Tejpar Q, et al. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol. 2008;22:237-242. (Pubitemid 351676383)
52. Mallon PT, McKay D, Kirk SJ, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007:CD005573.
53. Wu GD. Nuclear hormone receptors and intestinal inflammation. Gastroenterology. 2007;133:1068. (Pubitemid 47494480)
54. Ajuebor MN, Swain MG. Role of chemokines and chemokine receptors in the gastrointestinal tract. Immunology. 2002;105:137-143. (Pubitemid 34146679)
55. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557-561.
56. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26-40. (Pubitemid 38962271)
57. Delgado MA, Elmaoued RA, Davis AS, et al. Toll-like receptors control autophagy. EMBO J. 2008;27:1110-1121.
58. Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol. 2008;216:183-192.
59. Danese.Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis. 2008;40:S225-228.
60. Foell D, Frosch M, Sorg C, et al. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344:37-51. (Pubitemid 38626135)
61. Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006;313:1126-1130.
62. Cash HL, Whitham CV, Hooper LV. Refolding, purification, and characterization of human and murine RegIII proteins expressed in Escherichia coli. Protein Expr Purif. 2006;48:151-159. (Pubitemid 43782625)
63. Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Microbiol. 2008;298:463-472.
64. Cimmino L, Martins GA, Liao J, et al. Blimp-1 attenuates Th1 differentiation by repression of ifng, tbx21, and bcl6 gene expression. J Immunol. 2008;181:2338-2347.
65. Yamashita M, Ukai-Tadenuma M, Miyamoto T, et al. Essential role of GATA3 for the maintenance of type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci. J Biol Chem. 2004;279:26983-26990. (Pubitemid 38812534)